Drugs / HW201877
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07373457 | Jun 2025 → Mar 2026 overdue | inflammatory bowel disease | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HW201877 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07373457 ↗ |
| Route | Oral | “Single or multiple oral doses of HW201877 capsules, and food effect of HW201877 capsules” NCT07373457 ↗ |